About Our Test: Test Performance
The SimpliPro Colon™ test is a laboratory service available only to healthcare providers that, we believe, will enable better compliance for diagnostic colonoscopy for patients presenting with symptoms associated with colorectal cancer. It is a blood-based test that measures and analyzes 11 protein markers associated with a risk of colorectal cancer. As a group, these proteins have been found to correlate with a higher or lower risk of positive diagnosis of colorectal cancer and/or advanced adenoma using diagnostic colonoscopy, compared to baseline risk in studies of patients with an elevated risk.
The SimpliPro Colon test is a laboratory developed test that fits seamlessly into routine workups for patients with an elevated risk of colorectal cancer. It has not been validated in an asymptomatic, screening population for colorectal cancer, and should not be used in place of a colonoscopy.
compliance reported with a blood test
The SimpliPro Colon test requires only a blood draw, fitting seamlessly into your everyday routine workups.
- The sample draw for the test can be performed right in your office or lab
- No new procedures for you and your staff to learn
- No handling of feces
- No waiting for at-home tests to be returned
- Clear, easy-to-understand patient results reported for both risk of colorectal cancer and advanced adenoma
The SimpliPro Colon test is a clinical laboratory service developed and offered by Applied Proteomics, Inc. The performance characteristics of the test were determined by Applied Proteomics in its San Diego, CA, clinical laboratory that is regulated by the Clinical Laboratory Improvements Amendments of 1988 (CLIA). The laboratory has been certified under CLIA to perform high-complexity clinical testing and is also accredited by the College of American Pathologists (CAP). This is a clinical test performed by Applied Proteomics and should not be regarded as investigational or for research.
- Blume, John E., et al. The discovery and validation of blood plasma protein-based classifier panels for colorectal cancer and advanced adenoma using a combined mass spectrometry- and ELISA-based workflow in studies including 1,605 patient samples [abstract]. In: Digestive Disease Week; 2016 May 21-24; San Diego, CA. Oral presentation.
- Epigenomics, Inc. Adherence to Minimally Invasive Testing (ADMIT). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2015 – [29 June 2015]. Available from https://clinicaltrials.gov/ct2/show/NCT02251782.